Agoracom Blog Home

Posts Tagged ‘Marijuana’

Empower $CBDT.ca Expands Its Online Education with the Support of EuroLife $EURO.ca to Promote the Benefits of Functional Mushrooms and Psilocybin to Positively Impact Health and Wellness $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:00 AM on Wednesday, May 27th, 2020

– Company is forming a global mushroom education initiative with EuroLife Brands that will leverage the cannvas.me platform

– new initiative expands the original agreement by formalizing a cloud-based, globally accessible, leading educational experience for patients, clinics, and academic circles to participate, learn, interact, and create information on the uses, treatments, and applications of mushrooms for health and wellness.

VANCOUVER, BC / May 27th, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (OTCQB:EPWCF) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated life sciences company, is pleased to announce that further to the definitive agreement announced on May 15th, 2020 the Company is forming a global mushroom education initiative with EuroLife Brands (“EuroLife”) that will leverage the cannvas.me platform.

The new initiative expands the original agreement by formalizing a cloud-based, globally accessible, leading educational experience for patients, clinics, and academic circles to participate, learn, interact, and create information on the uses, treatments, and applications of mushrooms for health and wellness. The global initiative will be positioned as an educational platform but will also accept clinical trial results, integrate with universities and academic circles, provide knowledge and a safe learning experience free from the outside influence of misinformation.

“Our global mushroom education initiative will provide significantly more information pertaining to the treatment of a number of ailments using plant-based treatment options,” said Steven McAuley, chairman and chief executive officer of Empower. “We are proud to bring premium health and wellness products to our patients online and in our clinics and mushrooms are already a part of our expanding product line in this category. We look forward to working with the team at EuroLife to launch this initiative in the very near future.”

“We have an opportunity to be one of the first online education platforms to deliver information on the benefits of using mushrooms for nutrition and health and wellness,” said Shawn Moniz, Chief Executive Officer, EuroLife Brands Inc. “Our Cannvas.me education portal is scalable and provides quick and easy access to Empower employees, medical professionals and retail consumers who are in need of this important information. We will continue to leverage our technology to move EuroLife forward.”

A report produced by Research and Markets estimates the global mushroom market was over US$38 billion in 2017 and forecasted to expand at a CAGR of 7.9 per cent from 2018 to 2026. Increasing consumer awareness regarding the health benefits offered by mushrooms is a key factor influencing the growth of the mushroom market at present. Consumer mushroom consumption in supermarkets, restaurants, hotels, and cafeterias are also expected to add to the market demand. Mushrooms are considered a super food as they contain protein, vitamins, minerals and antioxidants, with a great deal of nutritional value and micronutrients. They are low in carbohydrates, high in fiber, and a good source of B-vitamins (riboflavin, pantothenic acid, and niacin), iron, and selenium.

EuroLife and Empower will create a mushroom portal which will leverage the same technology platform used for EuroLife’s cannabis portal and will include educational modules on a wide range of topics. The platform will also incorporate dynamic and interactive elements to facilitate learning.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

About EuroLife Brands Inc.

EuroLife Brands is a vertically integrated enterprise focused on the pan-European health and wellness sector.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley

Chairman & CEO

[email protected]

604-789-2146

Investors: Dustin Klein

SVP, Business Development

[email protected]

720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws.All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.I

Spyder Cannabis $SPDR.ca Announces Corporate Update $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 8:17 AM on Tuesday, May 26th, 2020
  • Company is now awaiting receipt of its RSA (“Retail Store Authorization”) for its Niagara Falls dispensary located at 6474 Lundy’s Lane
  • Company is awaiting a final inspection of its dispensary scheduled for the beginning of June, at which point, it intends to begin operations at its Calgary dispensary, located at 104-58th Ave, SE, suite 140
  • In order to address the challenges presented by the COVID 19 crisis, the company has focus on building up the online and e-commerce components for its US Hemp CBD only locations, in Atlantic City and West Palm Beach.

Vaughan, Ontario–(May 26, 2020) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company”) and its wholly-owned associated applicants, The Green Spyder Inc. and Spyder Cannabis Subco Inc., is pleased to provide the following update:

Niagara Falls Cannabis Dispensary

Further to the announcement of receipt of its ROL (“Retail Operator License”), the company is now awaiting receipt of its RSA (“Retail Store Authorization”) for its Niagara Falls dispensary located at 6474 Lundy’s Lane. The company plans to begin operations at the location as soon as the RSA is issued and final inspection is completed, while ensuring it complies with COVID-19 provincial regulations and focusing on its curbside pickup and delivery business.

Calgary Cannabis Dispensary

Further to the announcement of receipt of its Conditional Cannabis License, the company is awaiting a final inspection of its dispensary scheduled for the beginning of June, at which point, it intends to begin operations at its Calgary dispensary, located at 104-58th Ave, SE, suite 140.

Online and e-Commerce

In order to address the challenges presented by the COVID 19 crisis, the company has focus on building up the online and e-commerce components for its US Hemp CBD only locations, in Atlantic City and West Palm Beach. Specifically, the company has launched a US website as well as an affiliate program to generate increased awareness of the Spyder brand at ShopSPDR.com.

Filing Extension of Annual Disclosure Documents Due to COVID-19

Due to circumstances created by the COVID – 19 pandemic Spyder will not be filing its audited financial statements and related management discussion and analysis for the fiscal year ended January 31, 2020 by the scheduled due date of June 1, 2020, as required under section 4.4(b) and section 5.1(1) of National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”).

As required by Ontario Instrument 51-502 Temporary Exemption from Certain Corporate Finance Requirements (OSC Instrument 51-502), BC Instrument 51-515 Temporary Exemption from Certain Corporate Finance Requirements (BC Instrument 51-515), Blanket Order 51-517 Temporary Exemption from Certain Corporate Finance Requirements (ASC Blanket Order 51-517) and Manitoba Blanket Order 52-502 Temporary Exemption from Certain Corporate Finance Requirements (Manitoba Blanket Order 52-502), the Company discloses the following:

• The Company’s management and other insiders will be subject to a trading black-out that reflects the principles in Section 9 of National Policy 11-207 – Failure-to-File Cease Trade Orders until its audited financial statements and related management discussion and analysis for the fiscal year ended January 31, 2020;

• The Company expects to file its audited financial statements and related management discussion and analysis for the fiscal year ended January 31, 2020 on or about July 15, 2020

About Spyder Cannabis Inc.

Spyder is a Cannabis, Vape and CBD retailer that operates in jurisdictions where the products are federally legal in both Canada and the United States. The Company, through its subsidiaries, is a retailer involved in the development of three retail business units. The first is the sale of Cannabis products, the second is the sale of Hemp CBD in the United States only, the third is the sale of smoking cessation products in Ontario.

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes statements containing certain ‘forward-looking information” within the meaning of applicable securities laws (‘forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur.

For more information, please contact:

Spyder Cannabis Inc.

Dan Pelchovitz
President & Chief Executive Officer
Telephone: 1.888.504.7737
Email: [email protected]

Eurolife Brands $EURO.ca and Empower Clinics $CBDT.ca Form Global Mushroom Education Initiative $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 6:59 AM on Tuesday, May 26th, 2020
  • New initiative expands the original agreement by formalizing a cloud-based, globally accessible, leading educational experience for patients, clinics, and academic circles to participate, learn, interact, and create information on the uses, treatments, and applications of mushrooms for health and wellness
  • Will be positioned as an educational platform but will also accept clinical trial results, integrate with universities and academic circles, provide knowledge and a safe learning experience free from the outside influence of mis-information

Toronto, Ontario–(May 26, 2020) –  EuroLife Brands (CSE: EURO) (FSE: 3CMA) (OTC PINK: EURPF) (“EuroLife” or the “Company”), a vertically integrated enterprise focused on the pan-European health and wellness sector, is pleased to announce that further to the definitive agreement announced on May 15th, 2020 the Company is forming a global mushroom education initiative with Empower Clinics Inc. (CSE: CBDT) (OTCQB: EPWCF) (FSE: 8EC) (“Empower“), a vertically integrated and growth-oriented life sciences company.

The new initiative expands the original agreement by formalizing a cloud-based, globally accessible, leading educational experience for patients, clinics, and academic circles to participate, learn, interact, and create information on the uses, treatments, and applications of mushrooms for health and wellness. The global initiative will be positioned as an educational platform but will also accept clinical trial results, integrate with universities and academic circles, provide knowledge and a safe learning experience free from the outside influence of mis-information.

“Our global mushroom education initiative will provide significantly more information pertaining to the treatment of a number of ailments using these alternative plant-based treatment options,” said Steven McAuley, chairman and chief executive officer of Empower. “We are proud to bring premium health and wellness products to our patients online and in our clinics and mushrooms are already a part of our expanding product line in this category. We look forward to working with the team at EuroLife to launch this initiative in the very near future.”

“We have an opportunity to be one of the first online education platforms to deliver information on the benefits of using mushrooms for nutrition and health and wellness,” said Shawn Moniz, Chief Executive Officer, EuroLife Brands Inc. “Our Cannvas.me education portal is scalable and provides quick and easy access to Empower employees, medical professionals and retail consumers who are in need of this important information. We will continue to leverage our technology to move EuroLife forward.”

A report produced by Research and Markets estimates the global mushroom market was over US$38 billion in 2017 and forecasted to expand at a CAGR of 7.9 per cent from 2018 to 2026. Increasing consumer awareness regarding the health benefits offered by mushrooms is a key factor influencing the growth of the mushroom market at present. Consumer mushroom consumption in supermarkets, restaurants, hotels, and cafeterias are also expected to add to the market demand. Mushrooms are considered a super food as they contain protein, vitamins, minerals and antioxidants, with a great deal of nutritional value and micronutrients. They are low in carbohydrates, high in fiber, and a good source of B-vitamins (riboflavin, pantothenic acid, and niacin), iron, and selenium. 

EuroLife and Empower will create a mushroom portal which will leverage the same technology platform used for EuroLife’s cannabis portal and will include educational modules on a wide range of topics. The platform will also incorporate dynamic and interactive elements to facilitate learning.

About Empower Clinics Inc.

Empower is a vertically integrated health & wellness brand with a network of corporate and franchised health & wellness clinics in the U.S. The Company is building its first hemp-derived CBD extraction facility and produces its proprietary line of cannabidiol (CBD) based products. The Company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

About EuroLife Brands Inc.

EuroLife Brands (CSE: EURO) (FSE: 3CMA) (OTCPK: EURPF) is a vertically integrated enterprise focused on the pan-European health and wellness sector.

For additional information:

Contact: [email protected] or visit EuroLifeBrands.com

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuers future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Companys Managements Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

Mota Ventures $MOTA.ca Signs LOI to Acquire Ecommerce Platform Leader Unified Funding, LLC, Which Generated $96.5m in Consumer Transactions in 2019 $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 1:02 PM on Saturday, May 23rd, 2020
  • Unified has a database of over one million customers and facilitated over $375,000,000(Cdn) in consumer transactions
  • Unified’s platform generates revenue from licensing, marketing and product fulfillment fees, supporting brands in skin care, essential oils, men’s health, weight management and CBD

VANCOUVER, BC / ACCESSWIRE / May 23, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company”) is excited to announce it has entered into a Letter of Intent (the “LOI”) dated May 21, 2020, to evaluate the acquisition (the “Proposed Transaction”) of Unified Funding, LLC (“Unified”). Since inception in 2015, Unified has generated a database of over one million customers and has facilitated over Cdn$375,000,000 in consumer transactions. Powered by its proprietary technology platform, Unified has created an eCommerce ecosystem to scale its brands and achieve profitability targets through data analysis, strategic customer acquisition and supply chain management. Founded by partners with more than a decade of eCommerce and technology experience, Unified has rapidly grown into a formidable business focused on aggressive expansion in the natural health products market. Unified’s diverse platform generates revenue from; licensing, marketing and product fulfillment fees supporting brands in skin care, essential oils, men’s health, weight management and CBD including MOTA’s recently audited Nature’s Exclusive brand. Figures presented in this news release were translated from US dollars into Canadian dollars using the Bank of Canada closing exchange rate on May 22, 2020 of US$1.00:Cdn$1.3892.

“A transaction with Unified is another step forward in our expansion as a global eCommerce business. This is the platform and personnel necessary for MOTA to launch and grow brands, such as Nature’s Exclusive, which we acquired from Unified in January of 2020. Unified has developed a comprehensive eCommerce platform that is ideally suited for the natural health products sector. Integration of their platform and the personnel to run it will allow us to rapidly deploy new products and expand into new natural health product segments and markets,” stated Ryan Hoggan, CEO of the Company.

Beyond Unified’s comprehensive eCommerce technology platform, their services assist brands with launching and scaling customer acquisition strategies. Through a worldwide network of media partners, Unified is able to closely monitor market trends to guide product innovation and marketing strategies that yield profitable results.

“We have created a very comprehensive eCommerce platform with a team of data analysis, strategic customer acquisition and supply chain management experts that has been proven effective for rapid expansion of natural health brands. We are hopeful that a transaction with Mota will allow our group to use our skills to expand into additional international markets, create new natural health brands and reach more consumers. Mota’s access to capital markets to raise growth capital to invest in customer acquisition will give us a distinct advantage to quickly scale, diversify and expand into new high growth product offerings,” stated Kevin Keranen, Chairman of Unified.

Readers are cautioned that the LOI entered into with Unified does not set forth the terms of the Proposed Transaction, nor have such terms been finalized. Completion of the Proposed Transaction is subject to a number of conditions, including, not limited to, completion of due diligence, negotiation of definitive documentation, and the receipt of any required regulatory approvals. The Proposed Transaction cannot be completed until these conditions are satisfied and there can be no assurance that the Proposed Transaction will be completed at all.

The Proposed Transaction is not expected to constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. The Company will provide further information regarding its review of Unified, and the Proposed Transaction, as that information becomes available.

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

About Unified Funding, LLC

Founded in 2015 by partners with more than a decade of eCommerce and technology experience, Unified has rapidly grown into a formidable organization focused on aggressive expansion in the natural health products market. Powered by its proprietary technology platform, the company has created an eCommerce ecosystem to scale its brands and achieve profitability targets through data analysis, strategic customer acquisition and supply chain management. For more information about Unified, please visit https://www.unifiedbrandlab.com/.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President & CEO at +604.423.4733 or by email at [email protected]or www.motaventuresco.com

Primo Nutraceuticals $PRMO.ca Receives NPN (Natural Product Number) from Health Canada $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 4:42 PM on Friday, May 22nd, 2020

– Received its NPN (Natural Product Number) from Health Canada.

– Primo Nutraceuticals hand sanitizers meet Health Canada’s requirements for safety, effectiveness and quality.

– In response to the increasing demand for hand sanitizers in Canada during the current COVID-19 pandemic, Health Canada has implemented an interim expedited licensing approach to help businesses like Primo to obtain the required authorizations to produce and distribute hand sanitizer.

VANCOUVER, British Columbia, May 22, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”) is pleased to announce that it has received its NPN (Natural Product Number) from Health Canada. Primo Nutraceuticals hand sanitizers meet Health Canada’s requirements for safety, effectiveness and quality.

In response to the increasing demand for hand sanitizers in Canada during the current COVID-19 pandemic, Health Canada has implemented an interim expedited licensing approach to help businesses like Primo to obtain the required authorizations to produce and distribute hand sanitizer. Consistent with the interim measure for alcohol-based hand sanitizers currently in place, Primo’s hand sanitizer can be distributed to healthcare and commercial settings across Canada.

The Natural Product Number NPN 80099466 issued to Primo will be located on every Primo product label distributed.

The Natural Product Number contains information about the natural health product and found to be safe, effective and of high quality under their recommended conditions of use. You can identify licensed natural health products by looking for the eight-digit Natural Product Number (NPN) or Homeopathic Medicine Number (DIN-HM) on the label.

Sales are to commence in June 2020. No purchase orders are yet in place.

To view the product brochure visit: https://www.primoceuticals.com/shop#!/Primo-Lemon-Hand-Sanitizer-60/p/197662415/category=0

About Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis related products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of “Primo” branded retail outlets – offering “Thrive,” “Primo,” and a selection of curated partner brands. The Company possesses proprietary formulas for cannabis edibles, topical, and tinctures. Primo is focused on building a strong presence in the hemp industry with the objective of extracting and selling cannabinoids (CBD) products in both Canada and the United States.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

“Andy Jagpal”

President and Director

For further information, please contact Zoltan, IR Representative at: 604-722-0305, or; [email protected]

To learn more about what this news means to the shareholders visit:

https://t.me/PrimoNutraceuticals

Shop: www.primoceuticals.com

www.twitter.com/prmonutra

www.thrivecbd.org

www.beautykitchen.net

www.marianna.ca

www.drinkdefy.com

Corporate: www.primonutraceuticals.com

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c8349cf6-4f9e-49b2-9769-53f0c3274f0d

Primo Hand Sanitizer
Primo Nutraceuticals hand sanitizers meet Health Canada’s requirements for safety, effectiveness and quality.

Mota Ventures $MOTA.ca Talks Strategy on Mushrooms and CBD $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 9:30 AM on Thursday, May 21st, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

Results of the 2019 calendar year audit of Nature’s Exclusive:

  • Revenue of Cdn$29,034,000
  • Net income of $3,505,000
  • Achieved a margin of over 12%

VANCOUVER, BC / ACCESSWIRE / May 21, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC PINK:PEMTF) (the “Company“) would like to thank all shareholders and investors for attending yesterday’s investor call. The main items addressed on the call were the completion of 2019 audit of the Nature’s Exclusive brand and the expansion of business in the natural health products sector through the proposed acquisition of Verrian.

The 2019 financial results for the Nature’s Exclusive brand is a strong indicator of the power of the Company’s eCommerce business model. This growth continued into 2020. For the months January through April 2020, the Company has generated revenue of Cdn$13,968,000 with related expenses of Cdn$13,514,000. Revenue has increased 188% for this time period over the same period during 2019. The Company’s customer acquisition and subscription retention strategies are yielding benefits through the year and into May where the Nature’s Exclusive brand has acquired over 17,613 customers from May 1st through May 18th. With over 60% of these customers electing into a subscription, the Company expects reduced costs in the following months, as customer acquisition expense is a one-time cost per customer.

As a leading business in the natural health products sector, we’ve been aggressively looking to expand our offering into growing segments of the market. Through this process, we identified psychedelic medicine as a unique opportunity, due to the overwhelming momentum of the sector and the incredible health benefits that can be obtained through derivative products.

The Company has come to terms to acquire Verrian, a leading company in the psychedelic medicine sector. Verrian owns and operates an established 110,000 square-foot pharmaceutical manufacturing facility in Germany that holds EU-GMP, ISO 14001, and narcotics manufacturing licenses. The facility and equipment of Verrian have been independently appraised at Cdn$10,600,000 and include an analytical laboratory and full pharmaceutical manufacturing suite.

Beyond the importance of this manufacturing asset, Verrian’s product commercialization process is already underway. The business has invested over Cdn$2,000,000 in clinical trials with two studies that are ongoing. These studies combined with our manufacturing abilities will uniquely prepare us to go-to-market once approval is granted.

Verrian’s product development pipeline is incredibly strong with two products named PSI Gen and PSI Gen+, which are both natural psilocybin extracts from organic mushrooms combined with metabolism-enhancing natural herbs. While there are many benefits patients may realize from utilizing psychedelic medicine, Verrian is focusing on opioid addiction reduction. This is an important mission as a company as it is estimated that over 13 million people in the world take opioids. For those individuals who have suffered a loss due to one’s addiction to a medically prescribed pharmaceutical, this holistic approach provided by Verrian and Mota is even more meaningful. In addition to treatments for opioids, new studies have demonstrated successful psilocybin treatments for both alcoholism and depression, substantially increasing the market size of potential patients. According to Marketdata, the United States market for alcohol and drug addiction rehab will be worth $42,000,000,000 in 2020, with over 15,000 private treatment facilities and growing.

“Our acquisition of Verrian is another step forward in executing our vision to use our powerful eCommerce platform for new and innovative natural health products. While we continue to grow and expand our CBD business units, we will also be ready to fully commercialize the technology created by Verrian. I look forward to working with Verrian’s incredibly talented team of clinical researchers and addiction medicine professionals within our existing ecosystem as it will uniquely position us as a leader in psychedelic medicine,” stated Ryan Hoggan, CEO of the Company.

Completion of the acquisition of Verrian remains subject to a number of conditions, including completion of due diligence, receipt of any required regulatory approvals and the negotiation of definitive documentation. For further information regarding the proposed acquisition, readers are encouraged to review the Company’s news release of May 19, 2020.

Conference replay

Canada/USA TF: 1-800-319-6413
International Toll: +1-604-638-9010
Replay Access Code: 4620

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President & CEO at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Empower $CBDT.ca Signs Term Sheet to Acquire Interest in Dosed Movie and Launches New #Psychedelics Company Dosed Wellness Ltd. $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 6:53 AM on Wednesday, May 20th, 2020
  • Empower enters into a term sheet to acquire an interest in the global royalty rights of Dosed Movie,
  • launches Dosed Wellness, a psychedelics brand,
  • launches new dedicated website www.dosedwellness.com and adds new team members dedicated to the new brand

VANCOUVER BC / May 20, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated life sciences company, is pleased to announce it has entered into a non-binding term sheet with Golden Teacher Films Inc. (“Golden“) to acquire a 10% interest in certain royalty rights, intellectual property rights and interest in Dosed Movie (“DOSED”), an award-wining documentary film about treating anxiety, depression and addiction with psychedelic medicine.

Under the terms of the agreement, the Company intends to issue $75,000.00 CAD of common shares in the capital of Empower (each, a “Share”) plus an aggregate payment of $25,000.00 CAD to the Vendors at the Closing. Further, the principals of Golden, Tyler Chandler and Nicholas Meyers will be offered consulting contracts to join the management team of Dosed Wellness Ltd.

The Company also announces the launch of a dedicated psychedelics division Dosed Wellness Ltd. (“Dosed Wellness”) and a new dedicated website www.dosedwellness.com that will leverage the operating assets of Empower. Dosed Wellness is uniquely positioned as an early mover in the psychedelics space with a network of physicians and clinics, advanced research opportunities, telehealth capabilities, and a growing base of over 165,000 patients.

The mental health crisis could cost the world $16 trillion by 2030 and according to Future Market Insights; the global behavioral health (non-pharmacological) market is expected to be valued at US$156 billion by 2028.

“Widespread legalization of psilocybin and psychedelics is inevitable, as clinical research is showing these compounds are uniquely useful for treating mental illness and addiction.” said Tyler Chandler, Director of DOSED. “Since billions of people worldwide suffer from these conditions, we need to establish infrastructure and patient-care competencies to serve this population as soon as the law allows. We’re thrilled to align with Empower Clinics, which has the strategic vision, existing client base and clinic network to continue to lead the plant-based medicine industry.”

“The opportunity to partner with DOSED to help bring down stigmas and advance the science of psychedelic treatment options is a meaningful step forward to vastly improving the mental wellness outcome for millions of people around the world.” said Steven McAuley, Chairman and CEO of Empower. “Now, with the additions of Tyler and Nick on our new management team, we will leverage their substantial psychedelics experience and network to take full advantage of Empowers’ clinic infrastructure, technology and access to patients.”

According to the World Health Organization depression is already the leading cause of disability worldwide (more than 322 million people suffer from depression) and is a major contributor to the overall global burden of disease.

Both MDMA and psilocybin, combined with a course of therapy, have received Breakthrough Therapy Designation (BTD) from the FDA in the US, which means both are one step closer to licensing approval.

“Our team is well connected in the psychedelic space and our expertise on the media side will help elevate the Empower brand. We’re also excited that Empower Clinics is acquiring an interest in DOSED, as their promotion of the film will help educate millions of people about the opportunities inherent in psychedelic medicine.” said Nicholas Meyers, Producer of DOSED. “When people see Adrianne’s inspiring and eye-opening journey in DOSED, they’ll want to know how to access these treatments, which is precisely the problem Empower Clinics is positioned to solve as we move towards clinical trials and legalization.”

Psychedelic medicines derived from or inspired by plants and fungi found in nature have the potential to redefine how mental health conditions could be treated over the course of the next decade. Prohibition Partners Psych: The Psychedelics as Medicine Report March 2020

ABOUT EMPOWER

Empower is a vertically integrated health & wellness brand with a network of corporate and franchised health & wellness clinics in the U.S. The Company is building its first hemp-derived CBD extraction facility and produces its proprietary line of cannabidiol (CBD) based products. The Company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company now offers COVID-19 testing options in the United States and physician-based consultations, to address COVID-19 concerns.

About Dosed Movie

After many years of prescription medications failing her, a suicidal woman turns to underground healers to try and overcome her depression, anxiety, and opioid addiction with illegal psychedelic medicine such as magic mushrooms and iboga. Adrianne’s first dose of psilocybin mushrooms catapulted her into an unexpected world of healing where plant medicines are redefining our understanding of mental health and addiction. DOSED is directed and produced by Tyler Chandler and Nicholas Meyers is producer and director of photography. Visit www.dosedmovie.com to rent or own DOSED.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
Chairman & CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws.All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Mota Schedules Conference Call to Discuss Recent Announcements $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 5:20 PM on Tuesday, May 19th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / May 19, 2020 / MOTA VENTURES CORP. (CSE:MOTA)(FSE:1WZ)(OTC:PEMTF) (the “Company) a direct to consumer provider of a wide range of CBD products globally, is pleased to announce it will be hosting an investor conference call on Wednesday, May 20, 2020 with Mota Ventures management, Ryan Hoggan, CEO and Joel Shacker, President to discuss recent announcements.

The call will be held on May 20, at 1:15 pm Pacific Time.

Conference details:

Canada/USA TF: 1-800-319-4610
International Toll: 1-604-638-5340
Germany TF: 0800-180-1954

Callers should dial in 5 – 10 min prior to the scheduled start time and simply ask to join the call.

Conference replay

Canada/USA TF: 1-800-319-6413
International Toll: +1-604-638-9010
Replay Access Code: 4620

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com.

Mota Ventures $MOTA.ca Announces Completion Of Audit For Nature’s Exclusive Brand $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 11:31 AM on Tuesday, May 19th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC, CANADA / ACCESSWIRE / May 19, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC PINK:PEMTF) (the “Company“) is pleased to announce completion of an audit of the financial results of its Nature’s Exclusive brand through the twelve-months ended December 31, 2019.

  • 2019 audited financial results:
  • Revenue of Cdn$29,034,000
  • Associated expenses of Cdn$25,530,000
  • Net income of Cdn $3,505,000

“Completion of the 2019 audit is a culmination of an extensive team effort, and represents a significant milestone in the validation of our eCommerce business. The 2019 figures, where we achieved over 12% net income, provides us with a benchmark from which to measure our success in the 2020 fiscal year as we continue to build on the strong results generated by Unified,” noted Ryan Hoggan, Chief Executive Officer of the Company.

Throughout the 2019 calendar year, the Nature’s Exclusive brand was operated as a separate business segment of Unified Funding, LLC (“Unified“). The Company completed the acquisition of the brand, and the associated business line, on January 17, 2020. The audit was completed on carve-out financial statements of Unified, which present the standalone financial results of the brand. Figures presented in this news release were translated from US dollars into Canadian dollars using the Bank of Canada average annual exchange rate of US$1.00:Cdn$1.3269 for 2019.

The Company also announces that it has reached an agreement with Unified to amend the thresholds necessary for Unified to earn a bonus based on the financial results generated by the Nature’s Exclusive brand in the 2020 calendar year. Unified is entitled to earn a bonus payment based on the terms of the original transaction in which Mota acquired control of the brand, and the associated business line.

Under the terms of the amendment, Unified will continue to be entitled to a one-time bonus payment (the “Bonus Payment“) based on the revenue and profitability of Nature’s Exclusive in the 2020 calendar year. The Bonus Payment will be: (i) US$5,000,000, in the event gross revenue exceeds US$40,000,000 with a profit margin of at least ten percent; (ii) US$10,000,000, in the event gross revenue exceeds US$45,000,000 with a profit margin of at least ten percent; or (iii) US$15,000,000, in the event gross revenue exceeds US$50,000,000. The Bonus Payment will be payable in common shares of the Company (the “Bonus Shares“) based on an exchange rate of US$1.00 to C$1.30 and the greater of: (i) C$0.80; and (ii) the volume-weighted average closing price of the common shares of the Company on the Canadian Securities Exchange in the ten trading days prior to the last trading day of 2020. Any Bonus Shares issuable by the Company will be subject to the terms of a thirty-six month time release pooling arrangement, with applicable release dates calculated from the date of issuance of the Bonus Shares.

For further information regarding the Bonus Payment, and the acquisition of Nature’s Exclusive, readers are encouraged to review the Company’s news release of January 17, 2020.

“Revising the 2020 performance bonus will help to align our interests with Unified, and ensure they remain incentivized in the development of Nature’s Exclusive in the context of the current market. The brand has demonstrated strong financial results through 2020 to date, in spite of economic volatility and we look forward to continued success leading into the second half of 2020,” commented Ryan Hoggan, Chief Executive Officer of the Company.

About Mota Ventures Corp.

Mota is an established ecommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan

Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

North Bud Farms $NBUD.ca Announces Proposed Terms for Non-Brokered Private Placement of Units $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 9:19 AM on Tuesday, May 19th, 2020
  • Intends to complete a non-brokered private placement of units at a price of $0.05 per Unit for gross proceeds of up to C$2 million, subject to the Company’s receipt of minimum gross proceeds of C1$ million
  • Proceeds of the Offering will be used by the Company to meet its 12-month corporate and working capital requirements, which the Company believes is vital to ensuring efficient and consistent operations.

TORONTO, May 19, 2020 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company“) is pleased to announce that it intends to complete a non-brokered private placement of units (each a “Unit”) at a price of $0.05 per Unit for gross proceeds of up to C$2 million, subject to the Company’s receipt of minimum gross proceeds of C1$ million (the “Offering”).

Each Unit will be comprised of one common share in the capital of the Company (a “Common Share”) and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to acquire one Common Share (a “Warrant Share”) for a period of 24 months following the Closing Date (as defined below) at an exercise price equal to: (i) $0.075 if the Warrant is exercised within 12 months of the Closing Date, or (ii) $0.10 if the Warrant is exercised at any other time prior to expiry.

The Company may pay a cash fee or issue compensation securities to certain eligible finders in connection with the proceeds received by the Company from the sale of Units to subscribers introduced to the Company by such eligible finders.

The proceeds of the Offering will be used by the Company to meet its 12-month corporate and working capital requirements, which the Company believes is vital to ensuring efficient and consistent operations. Management believes that securing a 12-month cash runway is the most prudent step in attempting to secure the long-term viability of the Company. Failure to meet these capital requirements could force management to proceed with secondary options that may preserve less long-term value for shareholders. Subscription receipts will be held in escrow and released upon the filing of the Company’s 2019 financial statements.  The Offering is expected to close on or around June 1, 2020 (the “Closing Date”).

Anyone who is interested in participating in the current financing may email the Company at: [email protected]
The Offering is subject to certain conditions, including but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Canadian Securities Exchange (the “CSE”).

The Units will be offered: (i) on a private placement basis in all of the provinces and territories of Canada; (ii) in the United States on a private placement basis in reliance on Rule 506(b) of Regulation D or pursuant to other exemptions from the requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and in compliance with applicable United States federal securities laws and any “blue sky” laws or regulations of any state of the United States; and (iii) in such jurisdictions outside of Canada and the United States as determined by the Company on a private placement or equivalent basis.

Participation in the Offering will be open to anyone who qualifies under an accredited investor exemption and to existing shareholders (each an “Existing Shareholder”) of the Company as of the close of business on May 19, 2020 (the “Record Date”) who are eligible to participate in the Offering in reliance on the existing shareholder exemption under Canadian securities laws (the “Existing Shareholder Exemption”).

The aggregate acquisition cost to an Existing Shareholder relying on the Existing Shareholder Exemption cannot exceed $15,000 in any 12-month period, unless such Existing Shareholder has obtained advice regarding the suitability of the investment from a registered investment dealer in that Existing Shareholder’s jurisdiction. Persons who become shareholders of the Company after the Record Date are not permitted to participate in the Offering using the Existing Shareholder Exemption, however other exemptions may still be available.

The Units and any Warrant Shares issued upon the exercise of the Warrants issued in connection with the Offering will be subject to a statutory hold period in Canada of four months and one day following the Closing Date. Additional resale restrictions may apply under the laws of other jurisdictions.

This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, and these securities will not be offered or sold in any jurisdiction in which their offer or sale would be unlawful. The securities described herein have not been and will not be registered under the U.S. Securities Act, or any state securities laws of the United States. Accordingly, these securities will not be offered or sold to persons within the United States unless an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws is available.

In addition, the Company has resolved to re-price the 26.9M of currently issued and outstanding common share purchase warrants with exercise prices between $0.30/share and $0.40/share and various expiry dates, to a new reduced exercise price equal to $0.10 per share in order to align with the current proposed private placement and to encourage such warrant holders to exercise their warrants.  This reduction of warrant exercise prices is subject to certain conditions, including but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Canadian Securities Exchange (the “CSE”).

Additional Cost Cutting Measures

As of May 15, 2020, all members of senior management have been asked to agree to a 30% reduction in their cash-based compensation for the next four months, and to instead receive Common Shares in lieu.

The Company wishes to advise shareholders that it has successfully renegotiated approximately CDN$1 million in current payables by its subsidiary into a 24-month payment obligation. The restructuring improves the Company’s balance sheet and reduces monthly cash requirements moving forward. While this alleviates certain cash flow requirements, it does not affect the Company’s need to raise a minimum of $1 million of proceeds under the Offering.

Management Cease Trade Order Update

Additionally, the Company provides the following update on the previously announced management cease trade order (the “MCTO“) issued by the Ontario Securities Commission on March 31, 2020.

The MCTO was issued in connection with the delay by the Company in filing its annual financial statements, management’s discussion and analysis and related officer certifications for the financial year ended November 30, 2019 (collectively, the “Required Filings“) before the prescribed deadline of March 30, 2020.

The Company continues to work closely with its auditor and expects to file the Required Filings before the end of May 2020.

The Company is providing this status update in accordance with National Policy 12- 203 Management Cease Trade Orders (“NP 12-203“). The Company intends to follow the provisions of the Alternative Information Guidelines set out in NP 12-203, including the issuance of bi-weekly default status reports in the form of news releases, for as long as the Company remains in default. The Company confirms as of the date of this news release that there has been no material change in the information contained in the default announcement issued on March 13, 2020 and there is no other material information concerning the affairs of the Company that has not been generally disclosed.

Issuance of Common Shares for Services Rendered

The Company has proceeded with the issuance of 472,222 Common Shares, at an issue price of $0.18 per share, to an arm’s length advisor to the Company. The Common Shares, which are subject to a statutory hold period as required by applicable securities laws, are based upon the $85,000 cash value of the services rendered to the Company by the advisor.

About North Bud Farms Inc.

NORTHBUD owns and operates, through its subsidiaries, licensed cannabis facilities in Canada, California and Nevada. Bonfire Brands USA, the Company’s U.S. subsidiary, acquired cannabis production facilities in Salinas, California and Reno, Nevada in late 2019. The Salinas, California 11-acre farm is actively cultivating cannabis in its 60,000 sq. ft. of licensed greenhouse production space. The Reno, Nevada facility, located on 3.2 acres of land, was acquired through the acquisition of Nevada Botanical Science, Inc., and includes a world-class cannabis production, research and development facility with 5,000 sq. ft. of indoor cultivation space which holds medical and adult-use licenses for cultivation, extraction and distribution. Through its Canadian subsidiary, GrowPros MMP Inc., the Company built and owns a state-of-the-art purpose-built cannabis production facility located on 135 acres of agricultural land in Low, Quebec, Canada. The Low, Quebec facility currently has 24,500 sq. ft. of licensed indoor cultivation space; the Company has recently submitted its licence amendment application to Health Canada to add an additional 1,000,000 sq. ft. of outdoor cultivation space.

For more information visit: www.northbud.com

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements that include, but are not limited to, statements related to the expected proceeds of the Offering, the completion of the Offering including the timing thereof, the intended use of proceeds from the Offering, the timing of the Company filing the Required Filings and the submission of the Company’s license application to Health Canada. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms Inc.’s final long form prospectus dated August 21, 2018, which is available under the issuer’s SEDAR profile at www.sedar.com. 

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]